[CPT-11: new drug for metastatic colorectal cancer]

Tumori. 1999 Nov-Dec;85(6):A1-11. doi: 10.1177/030089169908500624.

[Article in Italian]

Authors

C Barone¹, C Pozzo, A Cassano

Affiliation

¹ Oncologia Medica, Università Cattolica del Sacro Cuore, Roma.

PMID: 10774581
DOI: 10.1177/030089169908500624

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents, Phytogenic / administration & dosage
Antineoplastic Agents, Phytogenic / adverse effects
Antineoplastic Agents, Phytogenic / pharmacokinetics
Antineoplastic Agents, Phytogenic / pharmacology*
Antineoplastic Agents, Phytogenic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Camptothecin / administration & dosage
Camptothecin / adverse effects
Camptothecin / analogs & derivatives*
Camptothecin / pharmacokinetics
Camptothecin / pharmacology
Camptothecin / therapeutic use
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Colorectal Neoplasms / drug therapy*
Colorectal Neoplasms / secondary*
Drug Administration Schedule
Humans
Irinotecan
Randomized Controlled Trials as Topic
Survival Analysis
Treatment Outcome

Substances

Antineoplastic Agents, Phytogenic
Irinotecan
Camptothecin